Organization | CHU La Timone

CHU La Timone Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2018

NCT03585465

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Alternative names

APHM - Hôpital Timone Enfants | APHM - La Timone | Assistance Publique Hôpitaux de Marseille (APHM) Hospital La Timone Adultes, France | CHU La Timone

Active Ingredients

Drugs in Phase 3 Trials (2)

propofol (diprivan) (1 trial)

sevoflurane (ultane) (1 trial)

Drugs in Phase 2 Trials (12)

capecitabine (xeloda) (1 trial)

cis-retinoic acid (1 trial)

cyclophosphamide (cytoxan) (1 trial)

etoposide (vepesid) (1 trial)

ifb-088 (1 trial)

irinotecan (Camptosar) (1 trial)

nivolumab (opdivo) (1 trial)

oxybutynin (ditropan) (1 trial)

riluzole (rilutek) (1 trial)

temozolomide (temodar) (1 trial)

vinblastine (velban) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Lung Injury (Phase 3)

Lymphoma (Phase 2)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 14